Argus downgrades Abbott Labs stock rating on guidance cut
Argus downgraded Abbott Laboratories (ABT) to Hold from Buy, citing near-term challenges including guidance cuts, reimbursement uncertainty, and competitive pressures. The company's Q3 2026 earnings met estimates, but it lowered full-year revenue guidance to 6%. Analysts have mixed reactions, with price targets ranging from $115 to $125. ABT plans to spin off its Nutrition business by 2027.
How this was made
The 30-second read
Why it matters
The guidance cut and downgrade are likely to trigger short‑term sell pressure, though the spin‑off may create future upside.
Market read
ABT's stock may decline in the near term as investors digest weaker guidance and downgrade.
What to watch
Potential upside from the upcoming Nutrition spin‑off could offset short‑term guidance concerns.
Background
Abbott Labs reported Q3 results and subsequently cut its full‑year guidance, prompting an analyst downgrade.
Ticker impact
Abbott Laboratories received a downgrade to Hold and cut its full‑year 2026 sales growth guidance.
downward pressure as the market prices in weaker outlook
Analyst downgrade combined with reduced sales growth guidance typically leads to sell‑side activity.
Market effects
Healthcare sector may see modest pullback as a large med‑tech firm signals slower growth.
U.S. markets could see slight dip in health‑care indices.
Limited to U.S. investors; minimal global ripple.
Counterpoint
Long‑term investors may view the hold rating as a buying opportunity given ABT's strong fundamentals.
Key entities
- companyAbbott Laboratories
U.S. healthcare and diagnostics firm.
- analystArgus Research
Downgraded ABT to Hold.
